

## COVID-19-Vaccine-Pfizer-BioNTech

S

### Sweet's syndrome: case report

A 52-year-old man developed Sweet's syndrome following administration of COVID-19-Vaccine-Pfizer-BioNTech.

The man presented with an acute skin eruption along with fever following 72 hours of the first dose of the COVID-19-Vaccine-Pfizer-BioNTech [Pfizer/BioNTech BNT162b2 mRNA vaccine; *route and dosage not stated*]. His medical history was significant for retroperitoneal liposarcoma in 2016 and therefore, he undergone radical surgery followed by unspecified adjuvant chemotherapy. His physical examination showed well demarcated, oval, tender, juicy plaques on the neck, trunk and upper limbs. Most of them showed overwhelming vesicles and pustules, while others had a target-like appearance due to a central haemorrhagic crust. He was also experiencing pain and dysesthesias of the distal phalanges of the hands. He was receiving paracetamol for fever. Therefore, he underwent punch biopsy from a lesion of the trunk for histopathological examination. Also, the second skin biopsy was taken from the perilesional skin for direct immunofluorescence. Histological examinations showed dense and diffuse mixed inflammatory infiltrate with a predominance of neutrophils, with subtle perivascular nuclear dust, dilated capillaries and prominent edema of the upper dermis. These findings were consistent with Sweet's syndrome. Therefore, he was diagnosed with Sweet's syndrome.

Therefore, the man started receiving treatment with methylprednisolone for 3 days followed by prednisone. His skin rash condition resolved within 3 weeks of treatment.